Aprea Therapeutics clears IND for APR-1051; updates on ATRN-119 Phase 1 at AACR

Aprea Therapeutics, Inc.

IND for next-gen WEE1 inhibitor APR-1051 cleared; first patient dosing expected June 2024 in Phase 1 ACESOT-1051 trial.
ATRN-119 (ATR inhibitor) Phase 1/2a: enrolling 550 mg cohort; no DLTs, no Grade 4+ AEs; stable disease in two patients (one on treatment 188+ days).
Preclinical data show APR-1051 has >50-fold reduced PLK off-target inhibition vs ZN-c3; well tolerated with minimal hematotoxicity in mice.
New preclinical ATRN-333 combination with lomustine for glioblastoma shows synergy; intracranial delivery via convection-enhanced device.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.